208 Long-Term Safety and Disease Control With Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies

Abstract

Ruxolitinib cream (RUX) is a Janus kinase (JAK) 1/JAK2 inhibitor in development for treating atopic dermatitis (AD). In two phase 3 studies, 1249 patients (≥12 y, Investigator’s Global Assessment [IGA] score of 2/3, 3%–20% affected body surface area [BSA]) were randomized 2:2:1 to twice- daily 0.75% RUX/1.5% RUX/vehicle cream for an 8-wk, double-blind, vehicle-controlled period (continuous treatment) followed by a double-blind long-term safety (LTS) period (assessments every 4 wk) to Wk 52. Patients on RUX remained on their regimen during the LTS period; patients initially on vehicle were rerandomized 1:1 to either RUX strength.